SMMT earnings: next report 2026-07-23, real EPS beat/miss history, analyst consensus Buy, P/E -10.53. Updated 2026-07-23.
Summit Therapeutics (SMMT) Research Hub
Summit Therapeutics (SMMT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 17.55 USD (+0.06%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.53, market cap 11.53B. This hub links to the full technical, earnings and options research available for SMMT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 17.55 USD (+0.06%) |
| 52-week range | 12.07 USD – 18.32 USD |
| Trend regime | Range |
| 14-day RSI | 68.1 (Bullish) |
| Trailing P/E | -10.53 |
| Market cap | 11.53B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-23 |
Available research for SMMT
Covered Call on SMMT: how it works, illustrative setup around the real 17.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SMMT: how it works, illustrative setup around the real 17.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SMMT: how it works, illustrative setup around the real 17.55 USD price, max profit/loss, breakeven and when to use it. Educational.
SMMT technical analysis: range, last 17.55 USD, RSI 68.1, 52w range 12.07 USD–18.32 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SMMT in?
Summit Therapeutics (SMMT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SMMT in an uptrend or downtrend?
As of 2026-09-11, SMMT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SMMT's trailing P/E ratio?
SMMT's trailing P/E is -10.53, with a market cap of 11.53B. See the earnings research page for full valuation detail.
When does SMMT next report earnings?
SMMT is next scheduled to report earnings on 2026-07-23, with a consensus EPS estimate of -0.27439 USD.